#amlsm
LightNews LightNews
mikkaelsekeres.bsky.social
Outstanding presentation on trial of AZA + Ven in younger #AMLsm adults by @DanPollyea #ASH24. Proud to be part of this collaboration @SylvesterCancer @UMiamiHealth! ORR 69%, MRD- 64% @ash-hematology.bsky.social
December 10, 2024 at 1:12 AM
rubenmesamd.bsky.social
Excited to run into #AMLSM stars @anand-88-patel.bsky.social & our own Dr Madelyn Burkart from @AtriumHealthWFB Comprehensive Cancer Center at #ASH24! @AtriumHealth @LevineCancer @WakeCancer @wakeforestmed @UChicagoLeuk @UCCancerCenter @bkragonmd.bsky.social
December 8, 2024 at 10:03 PM
emmamgroarke.bsky.social
My colleague @fergutierrezro1 giving an excellent talk at #ESHBMFS2024 on the clinical implications of clonal hematopoiesis in #telomere biology disorders 🧬; dependent on specific mutation with U2AF1, TP53, and chr1+ associated with #MDSsm and #AMLsm.
November 16, 2024 at 1:28 PM
jamesfanwu.bsky.social
Come check out the oral presentation of Evolution of survival disparities among #AYA patients with #AMLsm by Dr. Feliciano at 9:30am PST at the Grand Hyatt 🩸 Some behind the scenes prep from today! #ASH24 #ASHKudos #ASHTrainee @ash-hematology.bsky.social
December 8, 2024 at 5:02 PM
jamesfanwu.bsky.social
An amazing oral presentation of our #AMLsm #AYA #healthdisparities work by super-star resident Dr. Erin Feliciano 🌟#ASH24 #ASHTrainee #ASHKudos @ash-hematology.bsky.social

A 🧵 on some of the highlights of our findings:

1/x
December 8, 2024 at 6:40 PM
mariaamaya27.bsky.social
It’s ASH week! #ASHThrowback to 2019 Orlando plane ride with the amazing lab mate Shanshan Pei who is now a trailblazing independent investigator! He just came to visit and I look forward to his talk on Saturday. #AMLsm
December 2, 2024 at 3:10 PM
mariaamaya27.bsky.social
Fascinating talk by Shanshan Pei on a newly identified TFG-ROS1 fusion, that although rare it can cause CMML -> AML and can be targeted with ALK/ROS1 inhibitors. #AMLsm #ASH24
December 7, 2024 at 7:33 PM
amarkelkar.bsky.social
Part 2 on allogeneic stem cell transplantation for AML with
The Fellow On Call pod dropped today! Hope y'all find it helpful!
#BMTsm #AMLsm #MedSky #HemeSky
open.spotify.com/episode/1CQM...
December 11, 2024 at 10:25 PM
drchrishourigan.bsky.social
Hello, anybody home?
#medtwitter #bmtsm #amlsm
November 17, 2024 at 8:35 PM
vjhemonc.bsky.social
🩸 Today is World #Leukemia Day 🌎

🎥 Musa Yilmaz of @mdanderson.bsky.social discusses the critical role of MRD monitoring in patients with FLT3-mutated AML, as achieving MRD negativity is associated with a lower risk of relapse.

Learn more: 👉 buff.ly/ZYTnlpy

#WorldLeukemiaDay #AMLsm #HemOnc
September 4, 2025 at 9:01 AM
vjhemonc.bsky.social
🩸🎥 Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies.

Don't miss this insightful roundtable discussion from #iwAL25 with leading experts Eunice Wang, David Sallman, Gabriel Mannis, & Andrew Wei.

Watch now: 👉 buff.ly/VJJUbmz

#AMLsm #Leusm #Leukemia
November 11, 2025 at 10:01 AM
vjhemonc.bsky.social
It was wonderful to catch up with Joshua Zeidner at #EHA2025 to hear the updated results from the Beat AML Master trial of revumenib + aza-ven in older adults with NPM1-mutated or KMT2A-rearranged AML.

Watch here:
👉 buff.ly/sT0CECq

#AMLsm #Leusm #CTSM #BloodSky #HemeSky @leukdocjz.bsky.social
July 24, 2025 at 9:01 AM
swog.org
myeloMATCH is a large research study for people with #AML and #MDS. Treatment study MM1YA-S01 is for adults younger than 60 with AML. If you haven’t started treatment, ask your doctor about myeloMATCH. swog.org/MM1YA-S01. 1-800-4-CANCER. #leusm #AMLsm #leukemia
Clinical trial MM1YA-S01
January 13, 2025 at 9:03 PM
aacrjournals.bsky.social
From Blood Cancer Discovery: Intra-Leukemic Interactions Shape #AML Chemoresistance buff.ly/Zl42183

Intra-leukemic interferon signaling suppresses the expansion of leukemic subpopulations and contributes to chemoresistance in several experimental models of AML using primary patient samples. #AMLsm
January 22, 2026 at 5:06 PM
vjhemonc.bsky.social
Hear about the status of #CARTCell therapy in acute and chronic leukemias (ALL, AML, CLL) in our interview from #CART25 with Ulrich Jäger:

👉 https://buff.ly/3QhuKfw 👈

#Leusm #Leukemia #ALLsm #AMLsm #CLLsm #ImmunoOnc #HemOnc
February 20, 2025 at 11:00 AM
vjhemonc.bsky.social
It's always great when we catch up with Sanam Loghavi! 🧡

Thanks for stopping by - today we heard about all things #AMLsm!💡🩸🗞️

#LeuSM #HemOnc #ASH24 @ash-hematology.bsky.social
December 8, 2024 at 10:31 PM
vjhemonc.bsky.social
#ISAL2025 | Monica Cusan provides insight into organ infiltration in AML, highlighting current treatment approaches and the need for better diagnostic tools to identify extramedullary manifestations:

🎥 buff.ly/XejWcGi

#AMLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
March 24, 2025 at 2:00 PM
vjhemonc.bsky.social
Should precursor conditions, including CHIP and CCUS, be treated to prevent progression?

George Vassiliou shared his thoughts on this at #IBC2025 last week.

Watch the interview here:
👉 buff.ly/tDp0O0h 👈

#HemOnc #AMLsm #Leusm #MDSsm #BloodSky #MedSky
March 21, 2025 at 9:29 AM
vjhemonc.bsky.social
It’s always a pleasure to speak with ⁦Maria Teresa Voso - today she spoke about how we should treat APL, when and how we should use molecular testing in AML, and more!

Coming soon to vjhemonc.xn--com-wi13b

#ISAL2025 #HemOnc #AMLsm #Leusm
March 17, 2025 at 3:51 PM
vjhemonc.bsky.social
At #ASH24, Arnon Nagler commented on the value of non-T-depleted haploidentical transplantation in patients with secondary AML in first complete remission.

Click here to watch:
🎥 buff.ly/42ew36d

#BMTsm #AMLsm #Leusm #Leukemia #HemeSky #HemeOnc #BloodSky @ash-hematology.bsky.social
January 21, 2025 at 11:10 AM
vjhemonc.bsky.social
At #EHA2025, Harry Erba of @dukecancer.bsky.social outlined the updated results from the Phase III QuANTUM-Wild trial evaluating quizartinib combined with chemotherapy and as single-agent maintenance in newly diagnosed FLT3-ITD-negative AML.

Watch here:

👉 buff.ly/hMASdPZ 👈

#AMLsm #Leusm #CTSM
August 25, 2025 at 3:02 PM
vjhemonc.bsky.social
What is the current role of T-cell engagers and CARs in myeloid malignancies?🩸

Find out by watching our exclusive expert discussion from #iwCART25 with David Sallman, Marion Subklewe, Jae Park, & Andrew Kuykendall here:

👉 buff.ly/mQBv32R

#AMLsm #Leusm #MPNsm #ImmunoOnc #HemeSky #BloodSky
May 15, 2025 at 3:04 PM
vjhemonc.bsky.social
🎥 It was great to hear from Gail Roboz at #EHA2025! Dr Roboz provided insight into hot topics in AML from the meeting, covering menin inhibitors, venetoclax dose adjustments, & maintenance therapy.

Watch here:
👉 buff.ly/KRd1l8i

#AMLsm #Leusm #HemOnc #BloodSky #HemeSky #MedSky
June 22, 2025 at 3:01 PM
vjhemonc.bsky.social
In a wonderful joint discussion from #iwAL24, experts Richard Stone, Marina Konopleva, & Thomas Cluzeau speak on novel treatments & combinations in AML, commenting on mechanisms of resistance to venetoclax & approaching R/R disease:

🎥 https://buff.ly/3B3yHjY

#Leusm #AMLsm #HemOnc
November 29, 2024 at 12:00 PM
vjhemonc.bsky.social
MYC is required for tumor maintenance & presents a potential target for the treatment of acute leukemias.🩸

Learn about the development of strategies targeting MYC from Michael Andreeff:

👉 buff.ly/IY0vaTp 👈

#Leusm #AMLsm #ALLsm #ISAL2025 #HemOnc #Hematology #MedSky #BloodSky #HemeSky
April 7, 2025 at 9:01 AM